Ampio Pharmaceuticals, Inc.

294 articles with Ampio Pharmaceuticals, Inc.

• Ampio Pharmaceuticals Issues Letter to Stockholders

  8/3/2022

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.

• Ampio Pharmaceuticals Reports First-Quarter 2022 Financial Results

  5/16/2022

  Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, reported financial results for the first quarter ended March 31, 2022.

• 

  Ampio Stock Craters After FDA Rejects Trial Changes

  4/21/2022

  Ampio shares continue to fall following the company’s announcement that the FDA rejected proposed changes to a Phase III study of its treatment for osteoarthritis of the knee and other joints.

• Ampio Provides Regulatory Update - Apr 20, 2022

  4/20/2022

  Ampio Pharmaceuticals, Inc. announced the receipt of written responses from the United States Food and Drug Administration pursuant to a Type C meeting request submitted by the Company earlier in the year regarding the AP-013 trial results.

• Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights

  3/29/2022

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2021.

• Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call

  3/23/2022

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST. 

• Ampio Pharmaceuticals to Participate at the 34th Annual Roth Conference

  3/9/2022

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, will attend the 34th Annual ROTH Conference.

• Ampio Pharmaceuticals, Inc. to Host a Conference Call and Webinar

  3/2/2022

  Ampio Pharmaceuticals, Inc. announced that the Company will be hosting a webinar and conference call today at 4:30pm EST to provide an update on clinical and regulatory progress in osteoarthritis of the knee. 

• Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)

  3/2/2022

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today announced positive data from the modified Intent-to-Treat (mITT) population in the Company's AP-013 study, a Phase 3 clinical trial of the company's lead candidate, Ampion™.

• Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes

  2/10/2022

  Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, announced the appointment of Elizabeth Varki Jobes, Esq. to the Company's Board of Directors.

• Ampio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect Conference

  1/6/2022

  Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that it will present at the H.C. Wainwright Bioconnect Conference occurring virtually on January 10-13, 2022.

• Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders

  12/16/2021

  Ampio Pharmaceuticals today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.

• Ampio Pharmaceuticals Announces Pricing of $22.5 Million Registered Direct Offering

  12/13/2021

  Ampio Pharmaceuticals, Inc. announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 25,000,000 shares of the Company's common stock and warrants to purchase 15,000,000 shares of the Company's common stock at a combined purchase price of $0.90 per Share in a registered direct offering.

• Ampio Pharmaceuticals to Host Business Update Call with Chairman and CEO Mike Martino on Wednesday, Dec. 1

  11/29/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a business update call with its chairman and CEO, Mike Martino, at 4:30 p.m. EST on Wednesday, Dec. 1, 2021.

• Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael Martino

  11/23/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), today announced it will host a conference call with its CEO and Chairman, Michael Martino, who will provide a corporate and business on Wednesday, December 1, 2021, at 4:30 pm EDT/ 2:30 pm MT.

• Board Member Michael Martino to Become Interim Chairman and CEO of Ampio Pharmaceuticals, Mike Macaluso to Take Medical Leave

  11/22/2021

  Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, announced that Mike Macaluso is taking a one-year medical leave of absence from his role as Chairman and CEO, effective immediately.

• Ampio Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Ampio Pharmaceuticals, Inc. today reported results for the three- and nine-month periods ended September 30, 2021 and provided a corporate overview and business update.

• Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Business Update

  10/28/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended September 30, 2021 and provide a corporate business update on Wednesday, November 10, 2021, at 4:30 pm EDT/ 2:30 pm MT.

• Ampio Pharmaceuticals Strengthens Management Team and Board of Directors

  10/13/2021

  -- Holli Cherevka promoted to President and Chief Operating Officer -- Howard Levy joins as Chief Medical Officer -- J. Kevin Buchi and Michael A. Martino join Board of Directors -- Mike Macaluso, CEO of Ampio, realigns his responsibilities with the Ampio executive team and Board while undergoing medical treatment

• Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

  9/21/2021

  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) in the Phase II AP-019 clinical trial in India